| Autor: |
vander Straeten, Aurélien, Sarmadi, Morteza, Daristotle, John L., Kanelli, Maria, Tostanoski, Lisa H., Collins, Joe, Pardeshi, Apurva, Han, Jooli, Varshney, Dhruv, Eshaghi, Behnaz, Garcia, Johnny, Forster, Timothy A., Li, Gary, Menon, Nandita, Pyon, Sydney L., Zhang, Linzixuan, Jacob-Dolan, Catherine, Powers, Olivia C., Hall, Kevin, Alsaiari, Shahad K. |
| Zdroj: |
Nature Biotechnology; Mar2024, Vol. 42 Issue 3, p510-517, 8p |
| Abstrakt: |
Decentralized manufacture of thermostable mRNA vaccines in a microneedle patch (MNP) format could enhance vaccine access in low-resource communities by eliminating the need for a cold chain and trained healthcare personnel. Here we describe an automated process for printing MNP Coronavirus Disease 2019 (COVID-19) mRNA vaccines in a standalone device. The vaccine ink is composed of lipid nanoparticles loaded with mRNA and a dissolvable polymer blend that was optimized for high bioactivity by screening formulations in vitro. We demonstrate that the resulting MNPs are shelf stable for at least 6 months at room temperature when assessed using a model mRNA construct. Vaccine loading efficiency and microneedle dissolution suggest that efficacious, microgram-scale doses of mRNA encapsulated in lipid nanoparticles could be delivered with a single patch. Immunizations in mice using manually produced MNPs with mRNA encoding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain stimulate long-term immune responses similar to those of intramuscular administration. Automated fabrication of microneedle patch mRNA vaccines for COVID-19 may improve vaccine access. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink